Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker

Journal of the American Chemical Society

Volumn 132, Issue 10, 2010, Pages 3238-3239

  Laurieri, Nicola ^a   Crawford, Matthew H J ^a   Kawamura, Akane ^a   Westwood, Isaac M ^a   Robinson, James ^a   Fletcher, Al M ^a   Davles, Stephen G ^a   Sim, Edith ^a   Russell, Angela J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE N-ACETYLTRANSFERASES; BREAST CANCER; COLOR CHANGES; IN-CELL; NAPHTHOQUINONE; SELECTIVE INHIBITORS; SMALL MOLECULES; SPECIFIC DETECTION;

COLOR; ENZYMES; KETONES;

COLORIMETRY;

ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; N ACETYLTRANSFERASE 1; N-ACETYLTRANSFERASE 1; NAT2 ENZYME, MOUSE; TUMOR MARKER;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CELL LYSATE; COLORIMETRY; DISEASE MARKER; ANIMAL; BREAST TUMOR; CHEMICAL STRUCTURE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; HUMAN; METHODOLOGY; MOUSE;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; COLORIMETRY; FEMALE; HUMANS; ISOENZYMES; MICE; MODELS, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 77949353335     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja909165u     Document Type: Article

References (31)

1. For a review, see: Giepmans, B. N. G.; Adams, S. R.; Ellisman, M. H.; Tsien, R. Y. Science 2006, 312, 217.
2. For recent reviews, see: (a) Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Annu. Rev. Biochem. 2008, 77, 383.
3. (b) Soh, N. Sensors 2008, 8, 1004.
4. For selected recent examples, see: (a) Wright, A. T.; Song, J. D.; Cravatt, B. F. J. Am. Chem. Soc. 2009, 131, 10692.
5. (b) Verdoes, M.; Florea, B. I.; van der Marel, G. A.; Overkleeft, H. S. Eur. J. Org. Chem. 2009, 20, 3301.
6. (c) Richard, J.-A.; Jean, L.; Schenkels, C.; Massonneau, M.; Romieu, A.; Renard, P.-Y. Org. Biomol. Chem. 2009, 7, 2941.
7. (d) Zou, Y.; Yin, J. J. Am. Chem. Soc. 2009, 131, 7548.
8. (e) Tsukiji, S.; Wang, H.; Miyagawa, M.; Tamura, T.; Takaoka, Y.; Hamachi, I. J. Am. Chem. Soc. 2009, 131, 9046.
9. For selected recent examples, see: (a) Gallagher, S. S.; Sable, J. E.; Sheetz, M. P.; Cornish, V. W. ACS Chem. Biol. 2009, 4, 547.
10. (b) Hasegawa, Y.; Honda, A.; Umezawa, K.; Niino, Y.; Oka, K.; Chiba, T.; Aiso, S.; Tanimoto, A.; Citterioa, D.; Suzuki, K. Chem. Commun. 2009, 4040.
11. (c) Kamoto, M.; Umezawa, N.; Kato, N.; Higuchi, T. Bioorg. Med. Chem. Lett. 2009, 19, 2285.
12. (d) Halo, T. L.; Appelbaum, J.; Hobert, E. M.; Balkin, D. M.; Schepartz, A. J. Am. Chem. Soc. 2009, 131, 438.
13. (a) Weber, W. W.; Hein, D. W. Pharmacol. Rev. 1985, 37, 25.
14. (b) Wu, H.; Dombrovsky, L.; Tempel, W.; Martin, F.; Loppnau, P.; Goodfellow, G. H.; Grant, D. M.; Plotnikov, A. N. J. Biol. Chem. 2007, 282, 30189.
15. (c) Wang, H.; Liu, L.; Hanna, P. E.; Wagner, C. R. Biochemistry 2005, 44, 11295.
16. (a) Adam, P. J.; et al. Mol. Cancer Res. 2003, 1, 826.
17. (b) Butcher, N. J.; Tetlow, N. L.; Cheung, C.; Broadhurst, G. M.; Minchin, R. F. Cancer Res. 2007, 67, 85.
18. (a) Sim, E.; Westwood, I.; Fullam, E. Expert Opin. Drug Metab. Toxicol. 2007, 3, 169.
19. (b) Smelt, V. A.; Upton, A.; Adjayel, J.; Payton, M. A.; Boukouvala, S.; Johnson, N.; Mardon, H. J.; Sim, E. Hum. Mol. Genet. 2000, 9, 1101.
20. (a) Tozlu, S.; Girault, I.; Vacher, S.; Vendrell, J.; Andrieu, C.; Spyratos, F.; Cohen, P.; Lidereau, R.; Bieche, I. Endocr. Relat. Cancer 2006, 13, 1109.
21. (b) Sim, E.; Walters, K.; Boukouvala, S. Drug Metab. Rev. 2008, 40, 479.
22. (c) Wakefield, L.; Robinson, J.; Long, H.; Ibbitt, J. C.; Cooke, S.; Hurst, H. C.; Sim, E. Genes Chromosomes Cancer 2008, 47, 118.
23. (a) Minchin, R. F.; Hanna, P. E.; Dupret, J.-M.; Wagner, C. R.; RodriguesLima, F.; Butcher, N. J. Int. J. Biochem. Cell Biol. 2007, 39, 1999.
24. (b) Kawamura, A.; Westwood, I.; Wakefield, L.; Long, H.; Zhang, N.; Walters, K.; Redfield, C.; Sim, E. Biochem. Pharmacol. 2008, 75, 1550.
25. Russell, A. J.; Westwood, I. M.; Crawford, M. C.; Robinson, J.; Kawamura, A.; Redfield, C.; Lowe, E. D.; Laurieri, N.; Davies, S. G.; Sim, E. Bioorg. Med. Chem. 2009, 17, 905.
26. (a) Westwood, I. M.; Kawamura, A.; Fullam, E.; Russell, A. J.; Davies, S. G.; Sim, E. Curr. Top. Med. Chem. 2006, 6, 1641.
27. (b) http://louisville.edu/medschool/pharmacology/NAT.html.
28. It was presumed that the sulfonamide NH was undergoing proton exchange in all cases; for a related example, see: Wu, S.-P.; Huang, R.-Y.; Du, K.-J. Dalton Trans. 2009, 4735.
29. max was found to differ in the presence of mNat2 compared to aq. NaOH, consistent with the molecules being subjected to a different microenvironment through binding to the NAT enzyme.
30. For a related example, see: Kim, Y.-S.; Park, S.-Y.; Lee, H.-J.; Suh, M.E.; Schollmeyer, D.; Lee, C-O. Bioorg. Med. Chem. 2003, 11, 1709.
31. Hoover, J. R. E.; Day, A. R. J. Am. Chem. Soc. 1954, 76, 4148.